STOK - Stoke Therapeutics, Inc.
IEX Last Trade
11.28
0.020 0.177%
Share volume: 2,551
Last Updated: Thu 26 Dec 2024 04:30:01 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$11.26
0.02
0.18%
Fundamental analysis
24%
Profitability
25%
Dept financing
7%
Liquidity
75%
Performance
15%
Performance
5 Days
-3.08%
1 Month
-3.90%
3 Months
-11.29%
6 Months
-18.85%
1 Year
112.38%
2 Year
36.39%
Key data
Stock price
$11.28
DAY RANGE
$11.04 - $11.28
52 WEEK RANGE
$4.47 - $17.58
52 WEEK CHANGE
$111.59
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Edward M. Kaye
Region: US
Website: stoketherapeutics.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: stoketherapeutics.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Stoke Therapeutics, Inc. develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy.
Recent news